ADVERTISEMENT
2 /3 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Pharmaceuticals

Gilead, MacroGenics Join For Antibodies

by Rick Mullin
January 14, 2013 | APPEARED IN VOLUME 91, ISSUE 2

Gilead Sciences and MacroGenics have entered into a licensing deal under which the companies will develop four unspecified therapies using MacroGenics’ Dual Affinity Re-Targeting (DART) antibody platform, which is a bispecific technology that allows a single recombinant molecule to target two different antigens. Under the agreement, Gilead will pay MacroGenics, based in Rockville, Md., up to $30 million in licensing fees and up to $85 million in clinical milestone payments on the four development projects. Gilead, which will fund MacroGenics’ research on the project, will have exclusive worldwide rights for three of the programs and rights outside North America, Europe, Australia, and New Zealand for the fourth.

X

Article:

This article has been sent to the following recipient:

Leave A Comment

*Required to comment